Myovant Sciences is a healthcare company dedicated to revolutionizing women's and men's healthcare with its lead product candidate, relugolix. This once-daily, oral GnRH receptor antagonist has had success in late-stage clinical programs for the treatment of uterine fibroids, endometriosis, and prostate cancer. The company is also working on MVT-602, an oligopeptide kisspeptin-1 receptor agonist, for the treatment of female infertility. Myovant has a worldwide license from Takeda Pharmaceuticals, except for Japan and certain other Asian countries, to develop and commercialize relugolix, and an exclusive license for MVT-602. The majority shareholder of Myovant is Sumitovant Biopharma, Ltd., a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
Myovant Sciences Ltd.'s ticker is MYOV
The company's shares trade on the NYSE stock exchange
They are based in Brisbane, California
There are 201-500 employees working at Myovant Sciences Ltd.
It is https://www.myovant.com/
Myovant Sciences Ltd. is in the Healthcare sector
Myovant Sciences Ltd. is in the Biotechnology industry
The following five companies are Myovant Sciences Ltd.'s industry peers: